PDXO Model: A Significant Advancement in Precision Oncology

Facebook
LinkedIn

2024-12-02

Patient-Derived Xenograft Organoids (PDXOs) are 3D organoid models derived from patient-derived xenograft (PDX) tumor tissues.

Constructed using methods similar to those employed for patient-derived organoids (PDOs), PDXOs replicate the genetic, molecular, and structural features of the original tumors with exceptional accuracy.

These models surpass traditional 2D cell cultures by preserving the complex internal architecture of tumors, offering superior predictive power for selecting clinically relevant in vivo models and expediting drug development.

PDXOs effectively bridge the gap between in vivo PDX models and in vitro tumor studies, combining the strengths of both approaches.Applicable across various cancer types—including breast, colorectal, lung, and more—PDXOs serve as a valuable platform for investigating tumor heterogeneity, drug responses, resistance mechanisms, and metastasis.

At Medicilon, we have successfully developed nine PDXO models encompassing colorectal, pancreatic, gastric, leukemia, and prostate cancers. Each model undergoes stringent quality control processes, including the removal of mouse-derived fibroblasts, ensuring stable passaging, and cryopreservation.

As this field continues to advance, the transformative potential of PDXOs in cancer research and treatment is immense.

Search Medicilon

Medicilon Supports Moon Biotech’s Groundbreaking MNO-863 Probiotic Drug – Achieves Nearly 10% Weight Loss in 4 Weeks and Secures Dual Clinical Trial Trial Approvals

Zero Defects! Medicilon Supports MeiJi BioPharma’s Oral Paclitaxel Soft Capsule in Gaining FDA IND Approval

Global First! Medicilon Powers Tyercan’s Breakthrough Anti-Tumor Protein-Drug Tye1001 to U.S. and China IND Clearance

Contact Medicilon

Name
Address